Development of systemic therapy for hepatocellular carcinoma at 2013: Updates and insights

doi:10.3748/wjg.v20.i12.3135

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 12

This Article

(304)

(325)

(0)

(6404)

(10)

Peer-Review Report of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Topic Highlight

World J Gastroenterol. Mar 28, 2014; 20(12): 3135-3145
Published online Mar 28, 2014. doi: 10.3748/wjg.v20.i12.3135

Table 2 List of selected ongoing clinical trials on novel targeted therapy for hepatocellular carcinoma

Drug	Design	Phase	Status	NCT number
Single-agent
TKI
Dovitinib (TKI258)	Dovitinib vs sorafenib (1^st line)	Randomized phase II	Compl-eted	NCT01232296
Carbo- zantinib	Carbozantinib vs placebo (2^nd line)	Phase III	Ongoing	NCT01908426
c-MET inhibitor
Tivantinib	Tivantinib vs placebo (2^nd line)	Phase III	Ongoing	NCT01755767
INC280	INC280 (1^st line in c-MET expressing HCC)	Phase I/II	Ongoing	NCT01737827
Oncolytic poxvirus
JX594	JX594 vs placebo (2^nd line)	Randomized phase II	Ongoing	NCT01387555
Glypican-3
GC33	GC33 vs placebo (2^nd line)	Phase III	Compl-eted	NCT01507168
mTOR inhibitor
Everolimus	Everolimus vs placebo (2^nd line)	Phase III	Press release	NCT01035229
Temsir- olimus	Temsirolimus (1^st or 2^nd line)	Phase II	Abstract	NCT01251458
CC-223	CC-223 in solid tumors including HCC	Phase I/II	Ongoing	NCT01177397
Arginine deprivation therapy
ADI-PEG 20	ADI-PEG 20 vs placebo (2^nd line)	Phase III	Ongoing	NCT01287585
Combination
Sorafenib	Sorafenib + doxorubicin vs sorafenib	Phase III	Accrual	NCT01015833
Sorafenib	TACE + sorafenib vs TACE (ECOG 1208)	Phase III	Accrual	NCT01004978
Everolimus	TACE + everolimus vs TACE	Randomized phase II	Accrual	NCT01379521
Axitinib	TACE + axitinib	Phase II	Accrual	NCT01352728
Bevacizumab and Erlotinib	Bevacizumab + erlotinib vs sorafenib	Randomized phase II	Accrual	NCT01180959

TACE: Transarterial chemoembolization; TKI: Tyrosine kinase inhibitor; HCC: Hepatocellular carcinoma; c-MET: c-mesenchymal-epithelial transition factor-1.

Full Size Table

Citation: Chan SL, Yeo W. Development of systemic therapy for hepatocellular carcinoma at 2013: Updates and insights. World J Gastroenterol 2014; 20(12): 3135-3145
URL: https://www.wjgnet.com/1007-9327/full/v20/i12/3135.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i12.3135

Chan SL, Yeo W. Development of systemic therapy for hepatocellular carcinoma at 2013: Updates and insights. World J Gastroenterol 2014; 20(12): 3135-3145 [PMID: 24696599 DOI: 10.3748/wjg.v20.i12.3135]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.